We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Serologicals Corporation Announces UCOE Patent
News

Serologicals Corporation Announces UCOE Patent

Serologicals Corporation Announces UCOE Patent
News

Serologicals Corporation Announces UCOE Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Serologicals Corporation Announces UCOE Patent "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Serologicals Corporation has announced that the United States Patent and Trademark Office awarded, on September 27, 2005, patent no. 6,949,361 with respect to its recently acquired artificial ubiquitous chromatin opening element (UCOE) polynucleotide and related vectors.

Serologicals acquired the UCOE gene expression technology, which includes fifty-five issued and pending patents, on September 30, 2005.

UCOEs is designed to improve the yield, consistency and stability of protein production in cultured mammalian cells, allowing simpler and quicker generation of proteins at small scale for drug discovery and research, as well as quicker and easier isolation of stable, highly productive cell lines suitable for larger-scale manufacture of protein therapeutics.

David A. Dodd, President and Chief Executive Officer of Serologicals Corporation, commented on the receipt of the patent, stating, “Our recent acquisition of the UCOE technology exemplifies our ongoing focus on developing and acquiring innovative technologies that ensure we remain the leader in Bioprocessing technologies.”

“Our research and development groups will capitalize on this important technology for the benefit of our customers and will introduce it into our own manufacturing processes.”

“As a result of having applied these technologies, we anticipate supporting our customer's efforts to produce more consistent products with more efficient bioproduction systems.”

Dennis W. Harris, Vice President, Research & Development, Business Development and Chief Scientific Officer for Serologicals Corporation, will be in charge of inquiries about possible out-licensing opportunities using this patented technology.

Advertisement